REGN
NASDAQRegeneron Pharmaceuticals Inc.
Price$742.42+4.06 (+0.55%)
01:30 PM07:45 PM
News · 26 weeks57+13%
2026-04-122026-10-04
Mix2490d
- Other9(38%)
- Insider6(25%)
- SEC Filings4(17%)
- Earnings3(13%)
- Leadership1(4%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Regeneron Pharmaceuticals Inc.8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC New data explore inhibition of Factor XI for cancer-associated thrombosis, a leading cause of cancer death, where bleeding risk limits use of anticoagulants TARRYTOWN, N.Y., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of new clinical research at the European Society for Medical Oncology (ESMO) Congress 2026, t
- PRUbamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will advance ubamatamab into a confirmatory Phase 3 trial of this lethal cancer with limited treatment options TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDA
- PRPhase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight LossIn a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and muscle loss
- ANALYSTRegeneron Pharma upgraded by Argus with a new price targetArgus upgraded Regeneron Pharma from Hold to Buy and set a new price target of $850.00
- PRPress Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodiesSanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profitsSanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET Paris and Tarrytown, NY, Oc
- PRRegeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology AntibodiesREGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference call for investors and analysts today at 8:00 am ET/2:00 pm CET TARRYTOWN, N.Y. and PARIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announc
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call InformationParticipants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailin
- INSIDEREVP Commercial Mccourt Marion sold $2,002,458 worth of shares (2,346 units at $853.56) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 12,003 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $340,000 worth of shares (400 units at $850.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- FDAFDA Approval for PASATRU issued to REGENERON PHARMACEUTICALS, INCSubmission status for REGENERON PHARMACEUTICALS, INC's drug PASATRU (ORIG-1) with active ingredient GARETOSMAB has changed to 'Approval' on 08/19/2026. Application Category: BLA, Application Number: 761508, Application Classification:
- INSIDEREVP General Counsel and Secret Larosa Joseph J exercised 12,282 shares at a strike of $381.92 and covered exercise/tax liability with 9,019 shares, increasing direct ownership by 10% to 36,373 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECSEC Form N-PX filed by Regeneron Pharmaceuticals Inc.N-PX - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- INSIDEREVP Finance CFO Fenimore Christopher R. exercised 6,283 shares at a strike of $381.92 and covered exercise/tax liability with 4,599 shares, increasing direct ownership by 9% to 19,984 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- PRRegeneron Announces Investor Conference PresentationsTARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026Morgan Stanley 24th Annual Global Healthcare Conference at 1:05 p.m. ET on Monday, September 14, 2026Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, September 23, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website
- PRPasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at 56 weeks with a dramatic reduction in clinician-assessed flare-ups in adults with FOP TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in ad
- INSIDERDirector Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $320,000 worth of shares (400 units at $800.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- INSIDERDirector Zoghbi Huda Y exercised 800 shares at a strike of $376.69 and sold $640,000 worth of shares (800 units at $800.00) as part of a pre-agreed trading plan (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
- SECSEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRRegeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative InnovationEarly-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the recipients of the 2026 Regeneron Prize for Creative Innovation ("the Regeneron Prize"). This annual award celebrates outstanding early-career scientists, nominated by their research universities, whose creativity and innovation set new standards in biomedical research. Winners are chosen by a panel of Regeneron scientists based on the scientific merit, originality and creativity of 'dream project' proposals
- SECSEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- SECRegeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
- PRTessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive OfficerVeteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicinesSOMERVILLE, Mass., July 23, 2026 /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of Joseph Romanelli as President and Chief Executive Officer. Romanelli succeeds Michael Severino who has led the company since June 2022. Romanelli will join Tessera's board of directors and also join Tessera's founder, Flagship Pioneering, as a CEO-Partner.
- INSIDERDirector Ryan Arthur F sold $130,030 worth of shares (200 units at $650.15) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 17,303 units (SEC Form 4)4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
REGN FAQ
7 questionsWhat does Regeneron Pharmaceuticals Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults...Where does REGN stock trade?
Regeneron Pharmaceuticals Inc. (REGN) is listed on NASDAQ.What sector and industry is REGN in?
Regeneron Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Regeneron Pharmaceuticals Inc. go public?
Regeneron Pharmaceuticals Inc. (REGN) completed its IPO in 1991.What are analysts saying about REGN?
Regeneron Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Argus: Buy on 2026-10-01.What companies are similar to REGN?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), SNY (Sanofi). Compare REGN side-by-side with any of them on Quantisnow.How can I track REGN on Quantisnow?
Quantisnow aggregates Regeneron Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REGN to receive live email and push alerts on every new disclosure.